[IHuser]

imo... bottom is definitely in Viagra and Chapstick lubricant and fentanyl and analgesic preparation covid blue pills...PFE


Come and get it folks ...buy! buy! buy!~


IHuser

[TRADER99]

Bottom could be in and a decent hold here

[PowerPlay1]

Booster shot coming. PFE going to the 50sss plus $$

[IHuser]

imo.... myy flock knew i would throw this flick at this tiiiiime.....

PFE
IHuser

[DewDiligence]

ACIP endorses XBB/monovalent COVID boosters for_all_people >=6 months_of_age_by_13-1_vote:

https://video.ibm.com/channel/VWBXKBR8af4

The previous bilvalent booster shots are no longer recommended.

[IHuser]

imo... Chymeric scumbag......PFE

IHuser

[DewDiligence]

PFE establishes_mechanism_to monetize HLN stake via off-market sales:

https://www.sec.gov/Archives/edgar/data/78003/000007800323000093/pfizer13d-a3_hln.htm

PFE currently has a 32% equity stake in HLN, worth ~$12B at the current market price.

[DewDiligence]

Pavlovid weekly prescriptions have increased fourfold from their 2Q23 nadir, according to PFE’s CCO on today’s MS webcast. Weekly prescriptions are now running at about 60% of the peak 2023 level reached in January.

https://event.webcasts.com/viewer/event.jsp?ei=1630426&tp_key=a1d42d6790

[IHuser]

imo... chart for PFE is out of gas......retail market has abandoned this ticker in horror.....



IHuser

[IHuser]

imo...

Getting windy at PFE.....VIAGRA CHAPSTICK COVID FENTANYL


DID I MENTION FENTANYL


IHuser

[Vexari]

What is it about life

That makes it

So short

[DewDiligence]

(PFE)/SGEN—Tidvak shows statsig-superior OS/PFS/ORR compared_to_chemo at interim analysis in second-line cervical cancer in phase-3 “innovaTV 301” trial (https://www.clinicaltrials.gov/study/NCT04697628?term=NCT04697628 ):

https://www.businesswire.com/news/home/20230903632820/en

Details will be presented at a medical conference, but the hazard ratio for OS (the primary endpoint) must have been impressive to trigger a successful halt of the trial at the interim analysis.

Success of the innovaTV 301 phase-3 trial will surely be sufficient to convert the FDA’s 2021 accelerated approval of Tidvak (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tisotumab-vedotin-tftv-recurrent-or-metastatic-cervical-cancer ) to a full FDA approval.

PFE expects to close the $43B buyout of SGEN in late 2023 or early 2024.

[DCALongRun]

This is classic lol.

https://rumble.com/v3d9ucs-black-man-issues-fafo-about-new-vaccines.html

[IHuser]

imo...

Shit Show

IHuser


PFE

[IHuser]

imo.... KK we got you........relax honey, PFE

[IHuser]

imo... breaking

Gene Simmons to be hung by the tongue......... J 8- (~



PFE
IHuser

[Vexari]

It has already happened

Only for those

Misinformed

To catch up

When ready

[IHuser]

imo... phil you are watching me take these mf down.....

IHuser

[Vexari]

The secret epidemic

~~~ Sudden deaths ~~~
(10:02)

General population excess mortality

Nightbreed

[ASPRV]

Is the Enanta's complaints on Paxlovid fair? I mean, doesn't Pfizer have the same molecular structure reference in previous drugs?

[IHuser]

imo... PP!.......... 8-/ ....... really~?




IHuser




PFE

[PowerPlay1]

$PFE

[DewDiligence]

FDA approves PFE’s Abrysvo maternal vaccine_to_protect_infants_ from RSV during their first season:

https://finance.yahoo.com/news/u-fda-approves-abrysvo-pfizer-213100505.html

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age. ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains and was observed to be safe and effective.

PFE is the only company that has an RSV vaccine that protects infants by inoculating pregnant women.

The gestational time limit for the vaccination (no later than 36 weeks) is presumably to reduce the incidence of preterm birth, which had a slight increase relative to placebo in the clinical dataset for the vaccine.

p.s. LOL re the FDA’s woke language, wherein the vaccine is approved for “pregnant individuals” rather than pregnant women.

[IHuser]

imo...fentanyl and chapstick and viagra and covid blue pill tic tacs....bottoms up this sp going to OTC.

IHuser

[IHuser]

imo... IHuser(fire!-------------------------------------------------------------------->*%*--->PFE^**""@!~******PFE*

[IHuser]

imo...

IHuser

[IHuser]

imo...5G cell tower tech dudes with families at home got punctured with projectiles under Putin.....and US nationals would be in the dark if Trump not discussed it 5G,,,haha 6G publicly...NEXT!....loving the show....thank-you.

PFE

IHuser

[DewDiligence]

FDA approves PFE’s Elrexfio—(elranatamab)—for rrMM:

https://finance.yahoo.com/news/pfizer-elrexfio-receives-u-fda-180800306.html

This is an accelerated approval for patients who have failed four or more prior therapies, so the addressable market for this indication is pretty small. PFE plainly intends to move Elrexfio in earlier lines of treatment, where the addressable market is larger—and the competition is stiffer.

Elrexfio is a bispecific mAb injected subcutaneously once per week (or every other week after one year). Elrexfio is currently under review by the EMA (#msg-171269528).

[IHuser]

imo.....

Vex, DY, Ofspring, IHuser

PFE

[Vexari]

Episode 4 of the Breaking Point documentary series

~~~ Features multiple experts explaining the depth of the deception ~~~
(29:47)

Behind the pandemic

For more updates, visit: http://www.brighteon.com/channel/hrreport

NaturalNews

[Vexari]

U.S. Military Arrests Pfizer CEO Albert Bourla

~~~ For Crimes Against Humanity ~~~
(11:14)

The Digital Soldier Press

[IHuser]

imo...depending on one's faith in true internet news.....it is circulating and appears that CEO of Pfizer, Albert Bourla, has been apprehended by the US Military for crimes against humanity.....our efforts at ihub message boards do not go unnoticed.


IHuser

[Vexari]

It's much more than that

Different lots can be designated

To different groups in varying locations

All while keeping tabs on their effectiveness

Experimental drugs need honing

Fitting a particular agenda

While keeping results hidden

[Vexari]

Vaccine roulette

~~~ 1982 NBC Documentary ~~~
(1:28)

No sugar added

[Vexari]

How bad is my batch

Lethality - a measure of toxicity (3:22)

Batch codes and associated deaths, disabilities and illnesses for Covid 19 Vaccines

https://howbad.info/index.html

[IHuser]

imo...Pfizer roofied everybody DY....... like they said Cosby did...

smh hi Xena

IHuser

[XenaLives]

And you can bet the @^$#* politicians got the same vax...

[Vexari]

2,000 Athletes - collapsing, heart problems, blood clots

~~~ March 2021 to Jun 2023 ~~~
(1:36:05)

World orders review

[Vexari]

Australia Pfizer Senate

~~~ What about the 10 plus pages of adverse effects released in 2021 ~~~
(4:52)

Drwelch

Here is the link to the pdf:

https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf.

10 plus pages of adverse effects of the vaccine

This is why the pages were blank in the boxes the vials came in

Take a look at page 30.

Page 30: Appendix 1. List of adverse events of special interest

[Vexari]

Pfizer admits their employees

Received a different COVID vaccine

Than what the Public received
(0:35)

Pfizer employees were given a *special batch*

Different from what was forced into the general population

I would expect this to be the same one career politicians took

Either that or saline

This should not be

Vaccines are supposed to all be a clone of one another

With no variation

MAGAlionHAT

[Vexari]

Pfizer dodging every question

~~~ About the safety of the covid-19 Injections ~~~
(16:08)

PiratePete

[DewDiligence]

PFE 2Q23 CC transcript:

https://finance.yahoo.com/news/q2-2023-pfizer-inc-earnings-072624706.html

[PowerPlay1]

$PFE strong Buy.

[IHuser]

imo..pullback expected to PFE _1965 levels...

IHuser

[DewDiligence]

PFE reports 2Q23 results—reiterates_2023_non-GAAP EPS guidance and 2023_COVID-revenue_guidance—lowers_organic_growth_rate_slightly:

https://s28.q4cdn.com/781576035/files/doc_financials/2023/q2/Q2-2023-PFE-Earnings-Release.pdf

2Q23 revenue was $12.7B, -54% YoY but +5% YoY excluding COVID revenue. 2Q23 non-GAAP EPS was $0.67, down from $2.04 in 2Q22. 2Q23 COVID-related revenue was: $1.49B for Comirnaty (COVID vaccine), -79% QoQ and -83% YoY; and $139M for Paxlovid, -97% QoQ and -98% YoY.

PFE says 2Q23 was a nadir in COVID-related sales due to the gap between the end of government procurement and the start of commercial sales in September. PFE reiterated 2023 guidance of $13.5B for Comirnaty and $8.5B for Paxlovid; this guidance implies 2H23 revenue of $8.9B for Comirnaty and $4.4B for Paxlovid. However, if it becomes clear that COVID-related sales will fall well short of the above figures, PFE is prepared to cut operating costs accordingly.

2023 guidance for non-GAAP EPS remains unchanged at $3.25-3.45. 2023 revenue guidance is now $67-70B (upper bound reduced from $71B three months ago).

Guidance for 2023 organic sales growth excluding COVID products is now 6-8% (down from 7-9% three months ago); the main impetus for the lowered organic-sales guidance is ACIP’s less than enthusiastic support for PFE’s RSV vaccine, Abrysvo—i.e. the fact that ACIP did not unconditionally recommend Abrysvo for older adults, but rather said that patients should “discuss” Abrysvo with their healthcare provider.

The SGEN acquisition is still expected to close in 2023 or early 2024.


2Q23 CC slides:
https://s28.q4cdn.com/781576035/files/doc_financials/2023/q2/Q2-2023-Earnings-Charts-FINAL.pdf

Prepared CC remarks (synched with slides):
https://s28.q4cdn.com/781576035/files/doc_financials/2023/q2/Q2-2023-Earnings-Conference-Call-Prepared-Remarks-FINAL.pdf

[MiamiGent]

PFE With Covid revenues falling, Pfizer lays out growth plans and possible cost cuts
Max Gelman Senior Editor Endpoint News
August 1, 2023 11:55 AM EDT Pharma

https://stockcharts.com/h-sc/ui?s=PFE

As the Pfizer behemoth continues chugging along post-pandemic, the drugmaker is starting to clarify how its Covid-19 profits will turn into future growth.

For the first time Tuesday morning, Pfizer broke down detailed growth expectations from its slew of acquisitions made over the last year and a half. By 2030, Pfizer set a goal for at least $10 billion in Seagen-related revenue. It expects another $10.5 billion out of its deals for Biohaven, Arena, Global Blood Therapeutics and ReViral.

In total, Pfizer has targeted $25 billion by 2030 from its BD deals, and in Tuesday’s second-quarter earnings update another $5 billion is labeled as the “remaining gap,” making clear there is more to do. Pfizer CEO Albert Bourla didn’t face many questions on this topic, but when asked by Credit Suisse analyst Trung Huynh about whether non-Covid mid-term sales would hit high-single-digit growth ahead of that timeframe, Bourla said he remains confident.

“We’ll continue and we are at 6% right now. All these years we’re right here,” Bourla said. “The non-Covid business, the success of the [upcoming] launches is very important, so we’ll see a lot of things coming ahead of us.”

Pfizer’s Covid-19 vaccines, booster shots and its antiviral drug have been huge sellers, but are in decline. Its Covid-19 vaccine generated $36.8 billion in 2021 sales and $37.8 billion last year, while Paxlovid pulled in $18.9 billion in 2022 revenue — accounting for $93.5 billion in total.

Its deal spending, meanwhile, has added up to $67.2 billion: $43 billion for Seagen, $11.6 billion for Biohaven, $6.7 billion for Arena, $5.4 billion for Global Blood Therapeutics and $525 million for ReViral. That suggests the company may have at least $10 billion or more to spend to make up the last piece of its revenue goal.

David Denton
But with Covid vaccine sales expected to be down 64% compared with 2022, and Paxlovid revenue expected to decline 58%, both Bourla and CFO Dave Denton cautioned that cost-cutting measures may be coming, depending on revenue this fall.

“If our Covid-19 revenues are less than what we assumed, we are prepared to launch an enterprise-wide cost improvement program aligned with the longer-term revenue projections for our business,” Denton said.

Bourla added that Pfizer is expecting a new wave of Covid-19 cases in the second half of the year. Vaccine and Paxlovid demand are expected to increase in response, after which Pfizer will be able to more accurately predict sales.

“We expect the vaccination and treatment rates from the upcoming respiratory disease season to be a reliable predictor of trends in subsequent years,” Bourla said.

Several analysts asked Bourla and Denton for clarity on where specifically such measures will take place. Though they declined to divulge too many specifics, saying the details would come after the fall, Denton noted the cuts would likely be balanced between SI&A and R&D.

Overall, Pfizer reported $12.7 billion in revenue in the second quarter, down 53% from the same period a year ago. Covid-19 products made up the vast majority of that decline, Pfizer said; non-Covid revenues rose by 5%. The company also narrowed its projected full-year revenue from $67-$71 billion reported in the first quarter, to $67-$70 billion Tuesday.

AUTHOR
Max Gelman
Senior Editor
[e-mail]